Adverse cardiovascular events in patients treated with mogamulizumab

American Heart Journal Plus

Kirstin Cook¹  Jennifer M. Kwan²  Mariana L. Henry²  Angela Higgins²  Lauren A. Baldassarre²  Jason Cuomo²  Francine Foss³ 

[1] Department of Neurosurgery, University of California, Los Angeles School of Medicine, Los Angeles, CA, United States of America;Section of Cardiovascular Medicine, Yale University School of Medicine, New Haven, CT, United States of America;Section of Hematology, Yale University School of Medicine, New Haven, CT, United States of America;

关键词: Immunotherapy;    Mogamulizumab;    Cardiooncology;    Cardiotoxicity;    Lymphoma;   

DOI  :  

来源: DOAJ

【 摘 要 】

Study objectives: Mogamulizumab is an important treatment for T-cell leukemia and lymphoma. Adverse cardiovascular events (ACE) after mogamulizumab therapy have not been investigated. The aim of the study is to investigate ACE occurrence after mogamulizumab therapy. Methods: The International World Health Organization database, VigiBase, was analyzed from January 2013 to August 2019 for all adverse events, including ACE, that occurred after mogamulizumab treatment. ACE was defined as: cardiac death, myocardial infarction, heart failure, myocarditis, arrhythmia, vasculitis, thrombosis, palpitations and new hypertension. Results: ACE after mogamulizumab therapy affected 28 out of 650 unique patients (4.3%). Heart failure (42.8%) and ventricular arrhythmias (17.85%) were most common. ACE accounted for 10% of all fatal adverse outcomes, and 25% of all ACE were fatal. Time to fatal outcome was significantly shorter for patients with ACE compared to non-cardiovascular events, with a mean of 7.7 days (SD 6.91) vs 73 days (SD 90.7), p = 0.017, respectively. There was an increased total number of adverse cardiovascular events in patients greater than 65 and in Asian countries. Conclusions: Cardiovascular toxicity with mogamulizumab is a possible early occurring adverse outcome associated with high mortality.

【 授权许可】

Unknown